CAR-T cell therapies are being investigated for MG, as exemplified by a clinical case where a 33-year-old woman with refractory gMG was successfully treated with anti-CD19 CAR-T cells (Haghikia et al., 2023). This evidence concerns the gene CD19 and myasthenia gravis.